Abstract:Abstract Aims Identifying patients with established cardiovascular disease (CVD) who are at high risk of type 2 diabetes (T2D) may allow for early interventions, reducing the development of T2D and associated morbidity. The aim of this study was to develop and externally validate the CVD2DM model to estimate the 10-year and lifetime risks of T2D in patients with established CVD. Methods and results Sex-specific, competing risk-adjusted Cox proportional hazard models were derived in 19 281 participants with established CVD and without diabetes at baseline from the UK Biobank. The core model’s pre-specified predictors were age, current smoking, family history of diabetes mellitus, body mass index, systolic blood pressure, fasting plasma glucose, and HDL cholesterol. The extended model also included HbA1c. The model was externally validated in 3481 patients from the UCC-SMART study. During a median follow-up of 12.2 years (interquartile interval 11.3–13.1), 1628 participants with established CVD were diagnosed with T2D in the UK Biobank. External validation c-statistics were 0.79 [95% confidence interval (CI) 0.76–0.82] for the core model and 0.81 (95% CI 0.78–0.84) for the extended model. Calibration plots showed agreement between predicted and observed 10-year risk of T2D. Conclusion The 10-year and lifetime risks of T2D can be estimated with the CVD2DM model in patients with established CVD, using readily available clinical predictors. The model would benefit from further validation across diverse ethnic groups to enhance its applicability. Informing patients about their T2D risk could motivate them further to adhere to a healthy lifestyle.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify which patients who already have cardiovascular disease (CVD) are at a higher risk of developing type 2 diabetes (T2D). By early identification of these high - risk individuals, early intervention measures can be taken to reduce the development of T2D and its related health problems. Specifically, the main objective of the study is to develop and externally validate the CVD2DM model to estimate the risk of developing type 2 diabetes in the next 10 years and throughout life for patients with diagnosed cardiovascular disease. ### Research Background - **Prevalence trend of type 2 diabetes**: The prevalence of type 2 diabetes is increasing rapidly worldwide and is expected to reach 783 million people by 2045. - **Relationship between cardiovascular disease and type 2 diabetes**: Type 2 diabetes is a major risk factor for cardiovascular complications, and patients with both type 2 diabetes and cardiovascular disease are at a higher risk of cardiovascular events. - **Challenges in screening and prevention**: Currently, for patients with existing cardiovascular disease, there is still uncertainty regarding whether diabetes screening is required and the screening frequency, which poses a challenge for healthcare providers. ### Research Objectives - **Develop a prediction model**: Develop a model (CVD2DM model) that can estimate the 10 - year and lifetime type 2 diabetes risk for patients with diagnosed cardiovascular disease. - **External validation**: Validate the performance of the model in an independent cohort to ensure its reliability and applicability. ### Methods - **Study population**: - **Model development**: Use data from the UK Biobank and include 19,281 participants with diagnosed cardiovascular disease and without diabetes at baseline. - **External validation**: Use data from the UCC - SMART study and include 3,481 patients with diagnosed cardiovascular disease and without diabetes at baseline. - **Predictor variables**: - **Core model**: Age, current smoking status, family history of diabetes, body mass index (BMI), systolic blood pressure, fasting blood glucose, and high - density lipoprotein cholesterol (HDL). - **Extended model**: Add glycated hemoglobin (HbA1c) on the basis of the core model. - **Statistical analysis**: - Use the competing - risk - adjusted Cox proportional hazards model to build models for men and women respectively. - Evaluate the discrimination ability of the model by the c - statistic and the calibration ability of the model by the calibration plot. ### Results - **Model performance**: - **Internal validation**: The c - statistic of the core model is 0.69, and the c - statistic of the extended model is 0.78. - **External validation**: In the UCC - SMART study, the c - statistic of the core model is 0.79, and the c - statistic of the extended model is 0.81. - The calibration plot shows that the predicted 10 - year risk is basically consistent with the observed risk. - **Prediction of individualized treatment effects**: The model can also be used to estimate the extent to which an individual can benefit from lifestyle interventions. For example, participating in lifestyle interventions similar to the Diabetes Prevention Program (DPP) can significantly reduce the 10 - year and lifetime type 2 diabetes risk and extend the expected lifespan without type 2 diabetes. ### Discussion - **Uniqueness of the model**: The CVD2DM model is the first 10 - year and lifetime type 2 diabetes risk prediction model applicable to all patients with atherosclerotic cardiovascular disease, using features that are easily accessible in clinical practice and considering competing risks. - **Practical application**: Informing patients of their type 2 diabetes risk can motivate them to adhere more to a healthy lifestyle, thereby reducing the occurrence of type 2 diabetes and its related complications. ### Conclusion The CVD2DM model can effectively estimate the 10 - year and lifetime type 2 diabetes risk for patients with diagnosed cardiovascular disease, using predictors common in clinical practice. This model needs to be further validated in more diverse ethnic groups to enhance its applicability.

Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model

Lifetime and 10‐year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE‐T1D model

Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease

1350-P: Risk Models for the Development of Cardiovascular and Microvascular Events in Adults with Type 2 Diabetes in the FIELD Study

Development of a 5-year risk prediction model for type 2 diabetes in individuals with incident HbA1c-defined pre-diabetes in Denmark

Prediction of individual lifetime cardiovascular risk and potential treatment benefit: development and recalibration of the LIFE-CVD2 model to four European risk regions

A Risk Prediction Model for Heart Failure Hospitalization among Patients with Type 2 Diabetes

Cardiovascular disease risk prediction models for type 2 diabetes:verification in Chinese patients

Edwards' syndrome.

Prediction of type 1 diabetes using a genetic risk model in the Diabetes Autoimmunity Study in the Young.

Abstract 11917: Cardiometabolic Disease Staging and Major Adverse Cardiovascular Event Prediction in Two Prospective Cohorts

Time-to-Event Genome-Wide Association Study for Incident Cardiovascular Disease in People With Type 2 Diabetes

Effective questionnaire-based prediction models for type 2 diabetes across several ethnicities: a model development and validation study

Development and validation of a prediction model estimating the 10-year risk for type 2 diabetes in China

Development of machine learning-based models to predict 10-year risk of cardiovascular disease: a prospective cohort study

Incipient lingual cortical mandibular defect in a 10- to 12-year-old American Indian child.

A risk prediction model for heart failure hospitalization in type 2 diabetes mellitus

Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2

Development of a risk prediction model for postpartum onset of type 2 diabetes mellitus, following gestational diabetes; the lifestyle InterVention in gestational diabetes (LIVING) study

Prediction models for cardiovascular disease risk in the general population: systematic review

Performance of prediction models for nephropathy in people with type 2 diabetes: systematic review and external validation study